Cargando…

Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications

Cancers of the gastrointestinal (GI) tract greatly contribute to the global cancer burden and cancer-related death. Claudin-18.2(CLDN18.2), a transmembrane protein, is a major component of tight junctions and plays an important role in the maintenance of barrier function. Its characteristic widespre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jinxia, Xu, Zhiyuan, Hu, Can, Zhang, Shengjie, Zi, Mengli, Yuan, Li, Cheng, Xiangdong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036590/ https://www.ncbi.nlm.nih.gov/pubmed/36969060 http://dx.doi.org/10.3389/fonc.2023.1132319

Ejemplares similares

CLDN18.2-targeted molecular imaging and precision therapy of gastrointestinal tumors
por: Chen, Yan, et al.
Publicado: (2023)

CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
por: Wang, Canming, et al.
Publicado: (2023)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
por: Gao, Jing, et al.
Publicado: (2023)

Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors
por: Chen, Yan, et al.
Publicado: (2023)

Comment on: “Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors”
por: Li, Cuicui, et al.
Publicado: (2023)

Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
por: Kim, Seo Ree, et al.
Publicado: (2020)

A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy
por: Liang, Jie, et al.
Publicado: (2021)

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
por: Shitara, Kohei, et al.
Publicado: (2022)

Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2022)

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2023)

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

The Significance of the CLDN18-ARHGAP Fusion Gene in Gastric Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Wei-Han, et al.
Publicado: (2020)

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
por: Shah, Manish A., et al.
Publicado: (2023)

A literature review on the potential clinical implications of streptococci in gastric cancer
por: Zi, Mengli, et al.
Publicado: (2022)

Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis
por: Ungureanu, Bogdan Silviu, et al.
Publicado: (2021)

The IL1β-HER2-CLDN18/CLDN4 axis mediates lung barrier damage in ARDS
por: Ma, Xinhua, et al.
Publicado: (2020)

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
por: Huang, Yufan, et al.
Publicado: (2023)

ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
por: Konno, Hiroyasu, et al.
Publicado: (2022)

Analysis of the expression and genetic alteration of CLDN18 in gastric cancer
por: Li, Jian, et al.
Publicado: (2020)

Health Tract, No. 182: Medical Melange
Publicado: (1863)

Health Tract, No. 182: Medical Melange
Publicado: (1865)

Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
por: McDermott, Martina S.J., et al.
Publicado: (2023)

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
por: Lordick, Florian, et al.
Publicado: (2021)

Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
por: Singh, Prabhsimranjot, et al.
Publicado: (2017)

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
por: Qi, Changsong, et al.
Publicado: (2022)

Enrichment of CLDN18‐ARHGAP fusion gene in gastric cancers in young adults
por: Nakayama, Izuma, et al.
Publicado: (2019)

Case Report: A rare case of recurrent ascites after anti-Claudin18.2 antibody therapy for metastatic gastric cancer while responding sustainingly
por: Liu, Jinlu, et al.
Publicado: (2023)

New Imaging in Gastrointestinal Tract
por: Grassi, Roberto, et al.
Publicado: (2016)

Case Report: Perivascular epithelioid tumors of the gastrointestinal tract
por: Yan, Hui, et al.
Publicado: (2023)

Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma
por: Zhang, Zhenfa, et al.
Publicado: (2013)

Coumarins and Gastrointestinal Cancer: A New Therapeutic Option?
por: Banikazemi, Zarrin, et al.
Publicado: (2021)

Membranous and nuclear staining of CLDN18 in HPV‐independent and HPV‐associated endocervical adenocarcinomas
por: Du, Xiuzhen, et al.
Publicado: (2022)

Alcohol Use and Cancers of the Gastrointestinal Tract. Epidemiology and Preventive Implications
por: Rehm, Jürgen, et al.
Publicado: (2020)

The removal of foreign body ingestion in the upper gastrointestinal tract: a retrospective study of 1,182 adult cases
por: Wang, Xin, et al.
Publicado: (2021)

Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications
por: Kwon, Mi Jeong, et al.
Publicado: (2010)

Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family
por: Gao, Peipei, et al.
Publicado: (2021)

Inhibition of RNF182 mediated by Bap promotes non-small cell lung cancer progression
por: Liu, Yating, et al.
Publicado: (2023)

Rare variants confer shared susceptibility to gastrointestinal tract cancer risk
por: Zheng, Ji, et al.
Publicado: (2023)

The Expression of CLDN6 in Hepatocellular Carcinoma Tissue and the Effects of CLDN6 on Biological Phenotypes of Hepatocellular Carcinoma Cells
por: Lu, Yan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_il65iv5b45n7vms24vb9umbl7d